Bruker (BRKR) to Acquire Oncovision's Preclinical PET Imaging Business
- Wall Street falls as investors ready for Trump's inauguration
- IBM (IBM) Tops Q4 EPS by 13c, FY17 EPS Guidance Beats Consensus
- American Express (AXP) Misses Q4 EPS by 7c, FY17 EPS Guidance Tops Views at Mid-Poinit
- Skyworks Solutions (SWKS) Tops Q1 EPS by 3c, Offers Q2 Guidance, Announces Buyback
- After-Hours Stock Movers 01/19: (SWKS) (QRVO) (NVAX) Higher; (AFMD) (SGYP) (IBM) Lower (more...)
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Bruker (Nasdaq: BRKR) announced that it has signed an agreement to acquire the preclinical imaging business of Oncovision, a leading provider of innovative medical imaging devices used for the diagnosis of cancer. Financial terms of the agreement were not disclosed.
For the past five years, Bruker and Oncovision have partnered on an exclusive marketing agreement for Albira™ PET/SPECT/CT systems, and have developed the next-generation Albira Si with advanced Silicon photomultiplier (SiPM) technology for highest full field-of-view PET resolution and sensitivity. Oncovision and Bruker have also collaborated on a high-performance preclinical 3 Tesla SiPM-PET/MRI system, and are exhibiting a new, simultaneous SiPM-PET/MR insert for high-field magnets at WMIC 2016 in New York this week.
Dr. Wulf I. Jung, President of Bruker's Preclinical Imaging Division, stated: "With this planned acquisition, Bruker expects to strengthen its expertise and leadership in preclinical imaging. The unique, performance-leading SiPM PET technology and products developed by Oncovision in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, thereby facilitating quantitative imaging investigations."
Dr. Jung continued: "This unique and proprietary PET technology is one of the most important imaging modalities for translational research imaging. Our successful collaboration with Oncovision has led to the recent introduction of the performance-leading Albira Si PET/SPECT/CT system, and it now has also resulted in the first PET insert for high-field MRI systems for simultaneous PET and MRI measurements."
Ignasi Vivas, CEO of Oncovision, commented: "Bruker is the undisputed leader in preclinical imaging with a unique portfolio of imaging modalities. Our preclinical team is delighted to join a company so well known for their innovation and dedication to excellence. The combined resources will accelerate the development and integration of our molecular imaging technologies, and fulfill the growing demand from translational scientists."
As part of the agreement, Oncovision will retain its clinical human imaging business, including the MAMMI PET, a breast cancer diagnostic device based on PET imaging. Closing of the acquisition is expected late in the fourth quarter of 2016, and is subject to closing conditions. A German-Spanish team of the law firm CMS acted as legal adviser to Bruker.
Abbreviations: PET = Positron Emission Tomography, SPECT = Single Photon Emission Computed Tomography, CT = (X-ray) Computed Tomography, MRI = Magnetic Resonance Imaging, WMIC = World Molecular Imaging Conference.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wix.com (WIX) to Acquire flok
- CSS Industries (CSS) Names John Roselli as CFO
- Asta Funding, Inc. (ASFI) Commences 5.3M Share Tender Offer for Its Common Stock
Create E-mail Alert Related CategoriesCorporate News, Management Comments, Mergers and Acquisitions
Related EntitiesTesla, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!